[{"id":"031439da-5f9c-460c-8c05-2a1c5a400206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638206","created_at":"2021-01-18T17:51:53.397Z","updated_at":"2024-07-02T16:36:52.614Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies","source_id_and_acronym":"NCT03638206","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • CD19 expression • HLA-A positive","tags":["MET • CD19 • HLA-A • MSLN • CD22 • CD33 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • CD19 expression • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CAR-T cell immunotherapy • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2023","study_completion_date":" 03/01/2023","last_update_posted":"2019-12-11"}]